Sobi.IMMUNO-101 (anakinra), 0 NCT04324021
anakinra vs. standard of care
COVID 19 all comers
RECOVERY, 2022 NCT04381936
baricitinib vs. standard of care
COVID 19 all comers
Sobi.IMMUNO-101 (emapalumab), 0 NCT04324021
emapalumab vs. standard of care
COVID 19 all comers
ruxolitinib NOVARTIS, 0
ruxolitinib vs. control
COVID 19 all comers
TOCIVID (sarilumab), 0 NCT04322773
sarilumab vs. standard of care
COVID 19 all comers
sarilumab phase 2 high dose, 0 NCT04315298
sarilumab high dose (400mg) vs. placebo
COVID 19 all comers
sarimulab phase 2 low dose, 0 NCT04315298
sarilumab low dose (200mg) vs. placebo
COVID 19 all comers
First Affiliated Hospital of Wenzhou Medical University, 0 NCT04273581
thalidomide vs. placebo
COVID 19 all comers
ChiCTR2000030894 -TOCI, 0 ChiCTR2000030894
tocilizumab vs. favipiravir
COVID 19 all comers
NCT04356937, 0 NCT04356937
tocilizumab vs. placebo
COVID 19 all comers
BACC Bay Tocilizumab Trial, 2020 NCT04356937
tocilizumab vs. placebo
COVID 19 all comers
TOCIVID (tocilizumab), 0 NCT04322773
tocilizumab vs. standard of care
COVID 19 all comers
TOCOVID, 0 NCT04332094
tocilizumab vs. standard of care
COVID 19 all comers
NCT04330638, 0 NCT04330638
tocilizumab vs. standard of care
COVID 19 all comers
SAVE-MORE, 2021 NCT04680949
anakinra vs. placebo
COVID 19 hospitalized
ANA-COVID-GEAS, 0 NCT04443881
anakinra vs. standard of care
COVID 19 hospitalized
COV-BARRIER, 2021 NCT04421027
baricitinib vs. placebo
COVID 19 hospitalized
ACTT-2 (Kalil), 2020 NCT04401579
baricitinib vs. placebo
COVID 19 hospitalized
Sheng (Three C Study), 2020 NCT04365153
canakinumab vs. placebo
COVID 19 hospitalized
NCT04351152, 0 NCT04351152
lenzilumab vs. standard of care
COVID 19 hospitalized
NCT04432298, 2020 NCT04432298
pamrevlumab vs. standard of care
COVID 19 hospitalized
CORIMUNO-SARI-1 (non ICU), 2021 NCT04324073
sarilumab vs. standard of care
COVID 19 hospitalized
SARICOR, 0 NCT04357860
sarilumab vs. standard of care
COVID 19 hospitalized
SARCOVID, 0 NCT04357808
sarilumab vs. standard of care
COVID 19 hospitalized
Martinez-Sanz, 2020
tocilizumab vs. control
COVID 19 hospitalized
HNF Hospital Tocilizumab multidisciplinary team, 2020
tocilizumab vs. control
COVID 19 hospitalized
Colaneri, 2020
tocilizumab vs. control
COVID 19 hospitalized
Tsai, 2020
tocilizumab vs. control
COVID 19 hospitalized
SAM-COVID-19, 2020
tocilizumab vs. control
COVID 19 hospitalized
EMPACTA, 2020 NCT04372186
tocilizumab vs. placebo
COVID 19 hospitalized
NCT04412772 (ARCHITECTS), 0 NCT04412772
tocilizumab vs. placebo
COVID 19 hospitalized
Dongsheng Wang, 2020 ChiCTR2000029765
tocilizumab vs. standard of care
COVID 19 hospitalized
RCT-TCZ-COVID-19, 2021 NCT04346355
tocilizumab vs. standard of care
COVID 19 hospitalized
RECOVERY, 2021 NCT04381936
tocilizumab vs. standard of care
COVID 19 hospitalized
Soin AS (COVINTOC), 2021 CTRI/2020/05/025369
tocilizumab vs. standard of care
COVID 19 hospitalized
Rutgers, 2021
tocilizumab vs. standard of care
COVID 19 hospitalized
Declercq J (COV-AID), 2021 NCT04330638
tocilizumab vs. standard of care
COVID 19 hospitalized
NCT04577534 (COVIDSTORM), 0 NCT04577534
tocilizumab vs. standard of care
COVID 19 hospitalized
EU-CTR2020-001375-32 (PreToVid), 0 EU-CTR2020-001375-32
tocilizumab vs. standard of care
COVID 19 hospitalized
EU-CTR2020-001748-24 (ImmCoVA), 0 EU-CTR2020-001748-24
tocilizumab vs. standard of care
COVID 19 hospitalized
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 NCT04479358
tocilizumab vs. standard of care
COVID 19 hospitalized
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 NCT04434717
tocilizumab vs. standard of care
COVID 19 hospitalized
STOP-COVID (Guimarães), 2021 NCT04469114
tofacitinib vs. placebo
COVID 19 hospitalized
CORIMUNO-ANA-1, 2021 NCT04341584
anakinra vs. control
COVID-19 mild to moderate
Rodriguez-Garcia, 2020 EUPAS34966
baricitinib vs. standard of care
COVID-19 mild to moderate
Cantini, 2020
baricitinib vs. standard of care
COVID-19 mild to moderate
Cantini, 2020
baricitinib vs. standard of care
COVID-19 mild to moderate
Vergis, 2021 NCT04581954
fostamatinib vs. standard of care
COVID-19 mild to moderate
LIVE-AIR (Temesgen), 2021 NCT04351152
lenzilumab vs. placebo
COVID-19 mild to moderate
Vergis, 2021 NCT04581954
ruxolitinib vs. standard of care
COVID-19 mild to moderate
Capra, 2020
tocilizumab vs. control
COVID-19 mild to moderate
NCT04345445, 0 NCT04345445
tocilizumab vs. corticosteroids
COVID-19 mild to moderate
Murugesan, 2022
tofacitinib vs. standard of care
COVID-19 mild to moderate
ACTIV-1 abatacept, 2020 NCT04593940
abatacept vs. placebo
COVID-19 severe or critically
Fakharian, 2021 IRCT20151227025726N2
adalimumab vs. standard of care
COVID-19 severe or critically
Ana-COVID (Huet), 2020
anakinra vs. control
COVID-19 severe or critically
Kooistra, 2020
anakinra vs. standard of care
COVID-19 severe or critically
COV-BARRIER (critically ill), 2022 NCT04421027
baricitinib vs. placebo
COVID-19 severe or critically
Tziolos, 2021
baricitinib vs. standard of care
COVID-19 severe or critically
CAN-COVID, 2020 NCT04362813
canakinumab vs. placebo
COVID-19 severe or critically
ACTIV-1 cenicriviroc, 2020 NCT04593940
cenicriviroc vs. placebo
COVID-19 severe or critically
NCT04343989, 0 NCT04343989
clazakizumab vs. placebo
COVID-19 severe or critically
FORCE , 0 NCT04371367
complement inhibitors vs. standard of care
COVID-19 severe or critically
CORIMUNO19-ECU, 0 NCT04346797
eculizumab vs. standard of care
COVID-19 severe or critically
ACTIV-1 infliximab, 0 NCT04593940
infliximab vs. placebo
COVID-19 severe or critically
Kumar, 2021 CTRI/2020/05/024959
itolizumab vs. standard of care
COVID-19 severe or critically
V.Lomakin (CORONA), 2021 NCT04397562
Levilimab vs. placebo
COVID-19 severe or critically
RUXCOVID, 0 NCT04362137
ruxolitinib vs. placebo
COVID-19 severe or critically
DEVENT, 0 NCT04377620
ruxolitinib vs. placebo
COVID-19 severe or critically
Cao, 2020
ruxolitinib vs. vitamin C
COVID-19 severe or critically
sarilumab Sanofi phase 3 US, 0 NCT04315298
sarilumab vs. control
COVID-19 severe or critically
ARI-RAF (Della-Torre), 2020
sarilumab vs. control
COVID-19 severe or critically
sarilumab Sanofi phase 3 outside US, 0
sarilumab vs. placebo
COVID-19 severe or critically
REMAP-CAP sarilumab, 2021 NCT02735707
sarilumab vs. standard of care
COVID-19 severe or critically
CORIMUNO-VIRO, 0 NCT04341870
sarilumab azithromycin hydroxychloroquine vs. sarilumab
COVID-19 severe or critically
Lescure (Sarilumab 400mg), 2021 NCT04327388
sarilumab high dose (400mg) vs. placebo
COVID-19 severe or critically
Lescure (Sarilumab 200mg), 2021 NCT04327388
sarilumab low dose (200mg) vs. placebo
COVID-19 severe or critically
TACROVID, 2021 NCT04341038
tacrolimus vs. standard of care
COVID-19 severe or critically
Singh (TD-0903 10mg), 2021 NCT04402866
TD-0903 10mg vs. placebo
COVID-19 severe or critically
Singh (TD-0903 1mg), 2021 NCT04402866
TD-0903 1mg vs. placebo
COVID-19 severe or critically
Singh (TD-0903 3mg), 2021 NCT04402866
TD-0903 3mg vs. placebo
COVID-19 severe or critically
Amra, 2021 IRCT20170207032444N3
thalidomide vs. standard of care
COVID-19 severe or critically
Karakike (ESCAPE), 2021 NCT04339712
tocilizumab vs. anakinra
COVID-19 severe or critically
TOCI-RAF Study Group (Campochiaro), 2020
tocilizumab vs. control
COVID-19 severe or critically
Somers, 2020
tocilizumab vs. control
COVID-19 severe or critically
Mathilde, 2020
tocilizumab vs. control
COVID-19 severe or critically
Andrew, 2020
tocilizumab vs. control
COVID-19 severe or critically
Biran, 2020
tocilizumab vs. control
COVID-19 severe or critically
Klopfenstein, 2020
tocilizumab vs. control
COVID-19 severe or critically
Rashad, 2021 NCT04519385
tocilizumab vs. dexamethasone
COVID-19 severe or critically
CORON-ACT, 0 NCT04335071
tocilizumab vs. placebo
COVID-19 severe or critically
COVACTA (Rosas), 2020 NCT04320615
tocilizumab vs. placebo
COVID-19 severe or critically
NCT04377750 (HMO-0224-20), 0 NCT04377750
tocilizumab vs. placebo
COVID-19 severe or critically
Rosas (REMDACTA), 2021 NCT04409262
tocilizumab vs. placebo
COVID-19 severe or critically
Sarhan, 2022 NCT04779047
tocilizumab vs. remdesivir
COVID-19 severe or critically
ChiCTR2000030580, 0 ChiCTR2000030580
tocilizumab vs. standard of care
COVID-19 severe or critically
Rojas-Marte, 2020
tocilizumab vs. standard of care
COVID-19 severe or critically
Pereira, 2020
tocilizumab vs. standard of care
COVID-19 severe or critically
CORIMUNO-TOCI-1 (Group 1), 2020 NCT04331808
tocilizumab vs. standard of care
COVID-19 severe or critically
REMAP-CAP (tocilizumab), 2021 NCT02735707
tocilizumab vs. standard of care
COVID-19 severe or critically
Veiga, 2021 NCT04403685
tocilizumab vs. standard of care
COVID-19 severe or critically
Talaschian, 2021 IRCT20081027001411N4
tocilizumab vs. standard of care
COVID-19 severe or critically
Hamed, 2021
tocilizumab vs. standard of care
COVID-19 severe or critically
Karampitsakos, 2021
tocilizumab vs. standard of care
COVID-19 severe or critically
CORIMUNO-TOCI-ICU (Group 2), 2020 NCT04331808
tocilizumab vs. standard of care
COVID-19 severe or critically
MARIPOSA, 2021 NCT04363736
tocilizumab vs. tocilizumab
COVID-19 severe or critically
Belhassen-Garc??a, 2021
tocilizumab vs. tocilizumab
COVID-19 severe or critically
Sarhan, 2022 NCT04779047
tocilizumab vs. tocilizumab
COVID-19 severe or critically